Navigation Links
Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
Date:8/17/2010

DUBLIN and MYSTIC, Conn., Aug. 17 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Colin W. Stewart has been appointed President, Chief Executive Officer (CEO) and a member of the Company's Board of Directors effective August 16, 2010.  Mr. Stewart will be responsible for driving forward the Company's strategy to maximize the value of its lead product, AMR101, a new drug being studied in Phase 3 clinical trials for the treatment of high triglycerides. The Company announced last week that one of its Phase 3 trials, the MARINE trial, completed patient enrollment and randomization earlier than expected with top-line results now expected in early 2011.  

Mr. Stewart has more than 30 years of experience in executive management and commercial positions for pharmaceutical companies, including five years as President and CEO of CollaGenex Pharmaceuticals, Inc. where he was responsible for the company's growth leading to its successful sale in 2008.  

In addition, Mr. Stewart served ten years with the ASTA Medica Group, where he managed several business units in the United States and internationally. He began his career in sales and marketing for Winthrop Laboratories, Ltd. in the United Kingdom, and subsequently held a number of positions of increasing responsibility within the Sterling-Winthrop Group.

Dr. Declan Doogan, who has been serving as the Company's Interim CEO, will continue to support the Company as Chief Medical Officer providing Amarin access to the majority of his time.

Amarin's Chairman of the Board, Joseph Zakrzewski, commented, "We are very excited by the addition of Colin Stewart to the Amarin team.  He brings a wealth of commercial and executive management experience, which complements the already strong t
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
2. Medco Announces Agreement to Acquire United BioSource Corporation: A Global Medical Research and Scientific Services Leader to Advance Drug Safety and Knowledge
3. Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010
4. Volcano Corporation Presentation at Canaccord Genuity Growth Conference to be Webcast
5. Kensey Nash Corporation Announces Its Fourth Quarter and Fiscal Year End 2010 Earnings Release Date and Teleconference
6. DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference Call
7. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
8. CVS Caremark Corporation to Hold Conference Call to Discuss:
9. NOVT Corporation Completes Reverse/Forward Stock Split
10. Sysmex America and Medica Corporation Announce Distribution Partnership
11. Cardiogenesis Corporation to Report 2010 Second Quarter Results on August 4th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Reportlinker.com announces ... available in its catalogue:   ... for Optical Coherence Tomography (OCT) ... STUDY OBJECTIVES   ... to offer synopsis of the current and ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D ... results from the global Phase 3 PROMISE study ... simeprevir (TMC435) led to sustained virologic response 12 ... 79 percent of treatment-experienced genotype 1 chronic hepatitis ... all stages of liver fibrosis, when administered once ...
(Date:5/21/2013)... , May 21, 2013 U.S. spending on ... complex diseases such as cancer, multiple sclerosis and rheumatoid ... the end of 2015, according to a forecast released ... (Logo: http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we ... and health plans to act so they can continue ...
Breaking Medicine Technology:Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5
... May 4 Roche Public Affairs Director Stacy Quinn ... Star by the Healthcare Businesswomen,s Association (HBA) at the organization,s annual awards luncheon ... , , ... for detail and has earned the appreciation and respect of the management team, ...
... In conjunction with DURECT Corporation,s (Nasdaq: DRRX ) first quarter 2010 ... will be broadcast live over the internet on Monday, May 10, 2010 ... , , ... , , ...
Cached Medicine Technology:Roche's Quinn Honored as 2010 HBA Rising Star 2Roche's Quinn Honored as 2010 HBA Rising Star 3DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call 2
(Date:5/21/2013)... 2013 Spring is the perfect time ... markets filled with whole foods to weather perfect for ... the season the nutrition experts at Brilliant Nutrition highlight ... miss. , 1. Eating Locally, With the abundance of ... linger and explore, spring is a great time to ...
(Date:5/21/2013)... George Washington (GW) University School of Public ... launch of the Avance Center for the ... SPHHS, the Maryland Multicultural Youth Centers, the ... university-community partnership aims to address public health ... research, mutual capacity building and prevention efforts. ...
(Date:5/21/2013)... Parker Waichman LLP, a national law firm dedicated ... devices, is offering remarks on the closing argument of the ... E. Taylor v. Intuitive Surgical, 09-2-03136-5, Superior Court, State of ... Bloomberg report noted that the plaintiff’s attorney, after noting ... how it deployed its strategy to train doctors to use ...
(Date:5/21/2013)... Charlotte, NC (PRWEB) May 21, 2013 ... Greater Charlotte will hold a free Community Wellness Fair ... screenings. The fair will be held on Wednesday, May ... University City YMCA (8100 Old Mallard Creek Road, ... American Heart Association and the Mecklenburg County ...
(Date:5/21/2013)... 21, 2013 Arizona State University ... want to develop their ideas into solutions, products ... , The university is recruiting participants for AREA48 ... space” that provides early-stage entrepreneurs with opportunities to ... open to anyone, ASU is particularly seeking participation ...
Breaking Medicine News(10 mins):Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 2Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 3Health News:GW launches center to address health disparities in the Latino immigrant community 2Health News:GW launches center to address health disparities in the Latino immigrant community 3Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4
... Presentation is part of the U.S. Surgeon General,s national ... PHILADELPHIA, March 25 In the United States ... percent of people ages 2,to 19 years - are ... to have serious cardiovascular risk factors, such as high ...
... Latest Australian research into myopia or shortsightedness reveals that ... nerds. , We have literally busted the myth that ... personality characteristics. They are more likely to be ... A/Prof Paul Baird of the University of Melbournes Centre ...
... N.Y., March 25 Laerdal Medical,Corporation announces ... Organization. MedAssets Supply Chain Systems has awarded ... Therapy Products." The,contract is effective January 1 ... http://www.newscom.com/cgi-bin/prnh/20080325/NYTU018LOGO ), Bruce Cadwell, Laerdal,s ...
... 25 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM:TSX-V) announced today that ... FL. This Center is the Company,s first in the ... targeted for expansion. The opening of,the Miami Center brings ... According to the National Institute of Health, the prevalence ...
... Health System of New,Orleans will enhance patient ... process with technology from DocuSys, Inc., a,leading ... and presurgical care management system provider., ... Ochsner will,strategically focus on enhancing anesthesia medication ...
... China RuiTai,International Holdings Co., Ltd. (OTC Bulletin ... leading producer and distributor of,cellulose ether products ... today,announced that it has retained CCG Elite ... China RuiTai,s primary operations are conducted ...
Cached Medicine News:Health News:U.S. Surgeon General to Keynote Special Childhood Obesity Prevention Presentation in Philadelphia 2Health News:Mythbusted -- people who wear glasses aren't geeks 2Health News:Laerdal Medical Announces Strategic Relationship 2Health News:CRH Medical Corporation opens new Center in Miami, Florida 2Health News:Ochsner Health System Partners with DocuSys for Presurgical Care, AIMS and Medication Management Technology 2Health News:Ochsner Health System Partners with DocuSys for Presurgical Care, AIMS and Medication Management Technology 3Health News:China RuiTai International Holdings Retains CCG Elite for Investor Relations Services 2Health News:China RuiTai International Holdings Retains CCG Elite for Investor Relations Services 3
Sensitive Eyes drops keep soft contact lenses moist....
Lens Plus Sterile Saline Solution...
... Renu Multiplus No Rub formula is the ... today. All steps in one bottle without ... stores soft contact lenses and removes protein ... multi-purpose solution that contains Hydranate, a special ...
Sensitive Eyes sterile saline spray is the preservative-free aerosol saline solution for people with eyes sensitive to preservatives. Used for rinsing soft contact lenses after cleaning or thermal or...
Medicine Products: